Recent news on Renagel

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  Apr 25, 2007
WebWire (press release),Within the Renal business, sales of Renagel® (sevelamer hydrochloride) grew 16 percent to $137.4 million, up from $118.7 million in the first quarter a year

Ahead of the Bell: Genzyme Down  -  Apr 26, 2007
Forbes,Bear Stearns (nyse: BSC - news - people ) analyst Mark Schoenebaum said sales of kidney disease drug Renagel and osteoarthritis drug Synavisc were lower

Genzyme gets OK to resume testing of MS drug  -  May 17, 2007
Boston Globe,Also during yesterday's presentation, the company forecast that its kidney-dialysis drug Renagel , responsible last year for about $500 million of the

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  26 Apr 2007
WebWire (press release),Within the Renal business, sales of Renagel® (sevelamer hydrochloride) grew 16 percent to $137.4 million, up from $118.7 million in the first quarter a year

Ahead of the Bell: Genzyme Down  -  26 Apr 2007
Houston Chronicle,Bear Stearns analyst Mark Schoenebaum said sales of kidney disease drug Renagel and osteoarthritis drug Synavisc were lower than expected, but reiterated a

Genzyme finishes Renvela study in CKD patients  -  Apr 17, 2007
Renal Business Today,Renvela is a buffered form of Renagel and is intended to control serum phosphorus levels in dialysis patients. Genzyme said Renvela is being developed to

Genzyme successfully...  -  Apr 16, 2007
Boston Globe,Genzyme, a Cambridge biopharmaceutical company, has had success with Renagel, an existing treatment for patients with failed kidneys.

American Kidney Fund launches Part D grant program  -  Apr 3, 2007
Renal Business Today,The program covers bone disease medications, including Fosrenol, Hecterol, Phoslo, Renagel, Sensipar and Zemplar. Burton added that the AKF hopes to add

American Kidney Fund Launches Medicare Part D Grant Program for ...  -  Apr 3, 2007
PR Web (press release),This program covers common bone disease medications, including Fosrenol®, Hectorol®, Phoslo®, Renagel®, Sensipar® and Zemplar®.

Genzyme Gets Upgrade From Matrix  -  Mar 15, 2007
Houston Chronicle,Genzyme products include Renagel for kidney disease, Fabrazyme for Fabry disease and Thyrogen thyroid cancer. It is currently developing Myozyme for the

Dueling Fools: Rule Makers Rebuttal  -  Mar 13, 2007
Motley FoolAn investor can know a company inside and out, including how many patients will benefit from Genzyme's (Nasdaq: GENZ) Renagel for the control of serum

Genzyme Reports Financial Results for Fourth Quarter of 2006 and ...  -  Feb 14, 2007
Oxfordshire Bioscience Network (press release),Sales of Renagel® (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, are expected to reach $580-$590

Genzyme posts strong financials, despite AnorMed charges  -  Feb 15, 2007
Pharma Times (subscription),Another strong contribution to turnover came from Renagel (sevelamer HCl), which treats end-stage kidney disease and was up 22% to $135.1 million.

Zacks.com Announces That Nadine Wong Highlights: Genzyme  -  Feb 2, 2007
Business Wire (press release),Commercial strength elsewhere in the company’s portfolio could more than offset any Renagel weakness. Nadine Wong and her team anticipate a continued strong

Genzyme Has Fourth-Quarter Loss; Sees Higher Sales (Update2)  -  Feb 14, 2007
BloombergSales of Renagel, used for controlling phosphorus in patients on kidney dialysis, are expected to increase this year to $580 million to $590 million from

Nephrologists Report Practice Pattern Shifts in the Management of ...  -  Feb 1, 2007
PharmaLive.com (press release),...(such as Fresenius Medical Care's PhosLo) to non- calcium agents (such as Genzyme's Renagel and Shire's Fosrenol), particularly in the ESRD setting.

Renagel in New Dialysis Study Published in Kidney International  -  Jan 15, 2007
DG NewsThe results were drawn from the Renagel in New Dialysis study (RIND), a randomized open-label trial involving 127 patients new to hemodialysis at five

Renagel lowers mortality rate in trial  -  Jan 10, 2007
Renal Business Today,...--Genzyme Corp. said Monday that kidney disease patients taking Renagel had a significantly lower rate of death compared with patients using calcium-based

Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ...  -  Jan 10, 2007
Oxfordshire Bioscience Network (press release),Within the Renal business, Genzyme markets Renagel® (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis,

Genzyme Files for Approval of Sevelamer Carbonate for Patients on ...  -  Jan 4, 2007
Oxfordshire Bioscience Network (press release),Renvela is being developed as a next generation phosphate binder to replace Renagel® (sevelamer hydrochloride), the most-prescribed phosphate binder in the

Genzyme kidney drug lowers death rate in trial  -  Jan 8, 2007
Boston Globe,Genzyme Corp. said today that patients taking its kidney disease drug Renagel had a lower rate of death than patients taking some other treatments,

Genzyme kidney drug lowers death rate in trial  -  Jan 8, 2007
ReutersO: Quote, Profile , Research) said on Monday that patients taking its kidney disease drug Renagel had a lower rate of death than patients taking some other

Market Report -- In Play (GENZ)  -  Jan 8, 2007
MSN MoneyGenzyme: Findings show patients using Renagel experienced significantly lower rate of death than patients using calcium-based phosphate binders Co announces

Genzyme kidney drug shows promise in trial  -  Jan 8, 2007
Boston Business Journal,The Cambridge, Mass., biotech company (Nasdaq: GENZ) said patients using Renagel experienced a significantly lower rate of death compared with patients

Genzyme expects 2007 profit to rise on drug sales  -  Jan 9, 2007
Washington Post,Sales of the company's kidney disease drug Renagel rose 22 percent to $135 million. The company has submitted an application with US regulators for approval

One Liberty Square sold to Dallas realty company  -  Jan 9, 2007
Boston Globe,...s Renagel tablets, used to control blood phosphorus levels in chronic kidney disease patients, were linked to fewer deaths in a 127-person study than

Genzyme Shares Jump on Analyst Reports  -  Jan 4, 2007
Houston Chronicle,..."However, we believe Renagel's pressures are now widely known and that they could be limited to the fourth-quarter," he said.

(PRN) - ID Systems Unveils Two New Wireless Asset Management ...  -  Jan 8, 2007
Bolsamania.com,...(PRN) - Renagel in New Dialysis Study Published in Kidney International ... [+]. (PRN) - QuatRx Pharmaceuticals Reports Positive Results From a Phase 2

UPDATE 1-RESEARCH ALERT-Baird raises Genzyme to outperform  -  Jan 4, 2007
Reuters...--The brokerage said it still expects near-term competitive pressure on Renagel, the phosphate binder drug, but this pressure might be mitigated later this

Genzyme applies for kidney drug approval  -  Dec 21, 2006
Boston Globe,One of Genzyme's best selling drugs is Renagel, which prevents dangerous buildup of phosphate in the bloodstreams of kidney-dialysis patients and which

Genzyme Asks FDA for Renvela Approval  -  Dec 21, 2006
Forbes,Renvela is being planned as a replacement to the company's Renagel. The company has also started enrollment in a study involving kidney disease patients who

Genzyme files for FDA approval of new phosphate binder  -  Dec 21, 2006
Renal Business Today,Genzyme said Renvela is being developed to replace its existing phosphate binder Renagel. The biopharmaceutical company added that Renvela is a non-calcium,

Genzyme files for approval of kidney dialysis drug  -  Dec 21, 2006
ReutersThe drug, Renagel, controls serum phosphorus in patients with chronic kidney disease on kidney dialysis. Elevated serum phosphorus levels is associated with

Genzyme seeks approval for new kidney treatment  -  Dec 21, 2006
Boston Business Journal,The drug, to be known commercially as Renvela, is intended to replace the company's Renagel as a next generation phosphate binder.

Genentech and Seattle Genetics Announce Exclusive Global Licensing ...  -  Jan 9, 2007
Financial News USA (press release),The Cambridge, Mass., biotech company said patients using Renagel experienced a significantly lower rate of death compared with patients using calcium-based

(PRN) - MDVIP Announces Landmark Deal with Procter & Gamble ... [+]  -  Jan 8, 2007
Bolsamania.com,...(PRN) - Po Bronson Visits Borders(R) in Baileys Crossroads, Virginia for a Book Signing ... [+]. (PRN) - Renagel in New Dialysis Study Published in Kidney

(PRN) - MDVIP Announces Landmark Deal with Procter & Gamble ... [+]  -  Jan 8, 2007
Bolsamania.com,...(PRN) - Renagel in New Dialysis Study Published in Kidney International ... [+]. (PRN) - Harris Corporation Introduces New Mini-Sensor to Protect Military

(PRN) - MDVIP Announces Landmark Deal with Procter & Gamble ... [+]  -  Jan 8, 2007
Bolsamania.com,...(PRN) - Renagel in New Dialysis Study Published in Kidney International ... [+]. (PRN) - Provident Bankshares Corporation Announces Fourth Quarter 2006

Genzyme shares rally on analyst views  -  Jan 4, 2007
MarketWatch..."While we still anticipate near-term competitive pressure on Renagel, we see this pressure as transient, likely mitigated later this year with Renvela's

Thursday's Analysts' Upgrades and Downgrades  -  Jan 4, 2007
TheStreet.comNear-term competitive pressure on Renagel should be offset by the Renvela approval expected later this year. Health Net (HNT - commentary - Cramer's Take)

CV Therapeutics Seeks Europe's OK of Angina Drug and Genzyme Seeks ...  -  26 Dec 2006
Financial News USA (press release),The drug, to be known commercially as Renvela, is intended to replace the company's Renagel as a next generation phosphate binder.

Genzyme Files For Approval Of Sevelamer Carbonate For Patients On ...  -  Dec 23, 2006
Medical News Today (press release),Renvela is being developed as a next generation phosphate binder to replace Renagel(R) (sevelamer hydrochloride), the most-prescribed phosphate binder in

Genzyme applies for kidney drug approval  -  Dec 21, 2006
Boston Globe,One of Genzyme's best selling drugs is Renagel, which prevents dangerous buildup of phosphate in the bloodstreams of kidney-dialysis patients and which

Genzyme Asks FDA for Renvela Approval  -  Dec 21, 2006
Forbes,Renvela is being planned as a replacement to the company's Renagel. The company has also started enrollment in a study involving kidney disease patients who

Genzyme files for FDA approval of new phosphate binder  -  Dec 21, 2006
Renal Business Today,Genzyme said Renvela is being developed to replace its existing phosphate binder Renagel. The biopharmaceutical company added that Renvela is a non-calcium,

Genzyme files for approval of kidney dialysis drug  -  Dec 21, 2006
ReutersThe drug, Renagel, controls serum phosphorus in patients with chronic kidney disease on kidney dialysis. Elevated serum phosphorus levels is associated with

Genzyme seeks approval for new kidney treatment  -  Dec 21, 2006
Boston Business Journal,The drug, to be known commercially as Renvela, is intended to replace the company's Renagel as a next generation phosphate binder.

Water conservation work brings award for firm  -  Dec 5, 2006
Cambridge Evening News,Haverhill focuses on the bulk production of active pharmaceutical ingredients, especially for Renagel™, a phosphate binder for kidney patients on dialysis.

Genzyme expansion to help its research  -  Dec 1, 2006
San Antonio Express,Renagel, a drug used to treat end-stage renal disease, is among the company's top products. It generated $417 million in revenue last year,

Antiplatelet Agent 'Pletaal' Co-Promotion Agreement  -  Dec 12, 2006
PharmaLive.com (press release),Oxarol® (secondary hyperparathyroidism treatment), and Renagel® (hyperphosphatemia treatment), Chugai aims to continue improving total care for patients

Baird Sees Genzyme Losing Market Share  Sep 19, 2006
Outperform" and lowered his price target to $73 from $75, citing a recent survey of nephrologists that said the company's kidney disease drug Renagel could be ... -MSN Money

UPDATE 1-RESEARCH ALERT-Baird cuts Genzyme to "neutral"  Sep 19, 2006
...through competitive pressure that may impact intermediate-to-longer term growth prospects for both its substantial revenue generating drugs Renagel and Hectorol ... -Reuters

Genzyme downgraded to "neutral"  Sep 19, 2006
...that Genzyme's Renal Business is facing competitive pressures, which is likely to adversely affect the growth potential of the company's Renagel and Hectorol ... -newratings.com

Genzyme initiated with "buy"  Aug 31, 2006
...mentions that the company is well positioned for growth over the forthcoming three years, driven by the performance of Myozyme, Renagel, Fabrazyme, Hectorol ... -newratings.com

No problem with AKF Part D assistance program, HHS says  Aug 28, 2006
...teamed up to launch a program that will provide Renagel to Medicare patients who can't afford co-payments for the phosphorus drug. ... -Renal Business Today

Antiplatelet Agent 'Pletaal' Co-Promotion Agreement  -  12 Dec 2006
PharmaLive.com (press release),Oxarol® (secondary hyperparathyroidism treatment), and Renagel® (hyperphosphatemia treatment), Chugai aims to continue improving total care for patients

Decreased Hospitalizations and Health Care Costs Associated with ...  -  Nov 16, 2006
Drug Newswire (press release),According to the study investigators, patients treated with Renagel achieved an 11.0 percent reduction in the rate of all-cause hospitalization and a 13.3

Fresenius Medical Care Announces Positive Results from PhosLo CARE ...  -  Nov 22, 2006
PipelineReview.com (press release),KGaA today announced positive results from the PhosLo (calcium acetate) CARE-2 (Calcium Acetate Renagel Evaluation) study. The study demonstrated that when

Water conservation work brings award for firm  -  Dec 5, 2006
Cambridge Evening News,Haverhill focuses on the bulk production of active pharmaceutical ingredients, especially for Renagel™, a phosphate binder for kidney patients on dialysis.

Fresenius Medical Care Announces Positive Results from PhosLo CARE ...  -  Nov 21, 2006
PharmaLive.com (press release),The CARE-2 study was a randomized, controlled head-to-head comparison between PhosLo and Renagel with the addition of Lipitor (atorvastatin calcium),

Genzyme expansion to help its research  -  Dec 1, 2006
San Antonio Express,Renagel, a drug used to treat end-stage renal disease, is among the company's top products. It generated $417 million in revenue last year,

Business notebook  -  Nov 16, 2006
Boston Globe,Renagel boost: Genzyme Corp. said patients using the kidney drug Renagel were found in a study to have lower rates of hospitalization and shorter hospital

Market Report -- In Play (FMS)  -  Nov 21, 2006
MSN Money...in both treatment groups, there is no difference in cardiovascular calcification between patients treated with PhosLo and those treated with Renagel.

(PRN) - Bootie Beer Corporation To Buyback Shares on the Open ...  -  Nov 16, 2006
Bolsamania.com,...(PRN) - Decreased Hospitalizations and Health Care Costs Associated with Renagel Use ... [+]. (PRN) - American Lung Association Launches Information and

No problem with AKF Part D assistance program, HHS says  29 Aug 2006
...teamed up to launch a program that will provide Renagel to Medicare patients who can't afford co-payments for the phosphorus drug. ... -Renal Business Today

AKF, Genzyme launch Renagel assistance program  Jul 31, 2006
...have teamed up to launch a program that will provide Renagel to Medicare patients who can't afford co-payments for the phosphorus drug. ... -Renal Business Today

American Kidney Fund, Genzyme Announce New Medicare Part D ...  Jul 31, 2006
...announced today that they have launched a new program to provide Renagel® (sevelamer hydrochloride) free of charge to patients who are enrolled in a Medicare ... -WebWire

College’s ads questioned  Aug 12, 2006
Ron Renagel was perusing a local newspaper when he saw an ad promoting Central Arizona College that featured a large picture of Pinal County Sheriff ... -East Valley Tribune

Results Of Phase 2 Study Of Tolevamer For C. Difficile-Associated ...  Aug 16, 2006
Renagel(R) (sevelamer hydrochloride) controls serum phosphorus in patients with chronic kidney disease on dialysis, and WelChol(R) (colesevelam hydrochloride ... -Medical News Today

Results of Phase 2 Study of Tolevamer for C. difficile-Associated ...  Aug 16, 2006
Renagel® (sevelamer hydrochloride) controls serum phosphorus in patients with chronic kidney disease on dialysis, and WelChol® (colesevelam hydrochloride ... -Oxfordshire Bioscience Network

Research and Markets: Genzyme's Inorganic Growth Path and ...  Aug 3, 2006
Genzyme's revenue increased at a CAGR of 30.87% over 2001-04. This was primarily on account of Renagel, Fabrazyme and Cerezyme sales. ... -Business Wire

Genzyme given green light to make kidney drug at Irish plant  Aug 14, 2006
Waterford is already the primary tabletting and bottling centre for Renagel (sevelamer hydrochloride) – a drug used in patients with chronic kidney disease ... -In-PharmaTechnologist.com

Dennis Goldberg Appointed to CEO of Transport Pharmaceuticals  Aug 14, 2006
...$1 billon. At GelTex Pharmaceuticals, Dr. Goldberg was responsible for the development of RenaGel and Welchol. Transport's drug/delivery ... -Yahoo! News

Genzyme cleared for additional manufacturing in Ireland  Jul 25, 2006
Waterford is already the primary tableting and bottling center for Renagel. In 2005, the plant produced approximately three million ... -Pharmaceutical Business Review



Genzyme boosts jobs for Waterford  Apr 10, 2006
...has invested more than e200m and employs 300 people at it's biotechnology plant in Waterford, which supplies the global market with Renagel, a phosphate binder ... - Biotechnology Ireland

Zacks.com announces that Nadine Wong highlights: Genzyme  Mar 22, 2006
The 2006 top-line growth will be derived from Renagel, which should benefit significantly from the availability of Medicare Part D, which looks to lead a ... - Business Wire



Genzyme to invest E60m in Irish plant  Mar 1, 2006
The company's product line includes Renagel, used for treating patients on dialysis, and is prescribed to over 350,000 people worldwide. ... - Biotechnology Ireland,

Genzyme Reports Financial Results for Fourth Quarter of 2005 and ...  Feb 15, 2006
Revenue for Renagel® (sevelamer hydrochloride) for patients with end-stage renal disease is expected to reach $495-$505 million this year, compared with $417 ... - WebWire,

Jim Cramer's Stop Trading!: KeySpan Unlocked  Feb 17, 2006
Cramer was also bullish on Genzyme (GENZ:Nasdaq - commentary - research - Cramer's Take), citing strong prescription growth for Renagel last quarter due to ... - TheStreet.com

Analysts' Actions: A Daily Roundup of Street Research  Feb 16, 2006
Genzyme upgraded at Thomas Weisel: Thomas Weisel said it is upgrading GENZ to Outperform. Sees strong sales from Myozyme and Renagel in 2006. ... - TheStreet.com

Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue  Jan 9, 2006
Fourth-quarter revenue for Renagel(R) (sevelamer hydrochloride), a phosphate binder for patients with end-stage kidney disease on hemodialysis, grew 12 percent ... - MSN Money

Genzyme 4th-qtr revenue rises 22 pct on drug sales  Jan 9, 2006
Fourth-quarter revenue for Renagel, the company's drug for patients with end-stage kidney disease, rose 12 percent to $111 million. ... - MSN Money

New treatments possible for kidney disease  Jan 31, 2006
Dialysis drug is cost effective, study (December 2, 2005) -- A recent study suggests that sevelamer, sold as Renagel by Genzyme, Cambridge, Mass.,-- and a ... - Science Daily

S&P Cuts Alberto-Culver Shares to Hold from Buy  Jan 10, 2006
Renagel sales of $111 million are in line, $232 million Cerezyme sales were $9 million below our forecast, and $81 million Fabrazyme sales were $1 million below ... - BusinessWeek

Genzyme's Revenue Set to Climb  Jan 9, 2006
The kidney-disease drug Renagel saw a 12% increase in sales to $111 million, while the Fabry disease treatment Fabrazyme had a sales increase of 27% to $81 ... - TheStreet.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional